US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
AU2003209119A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
US8299108B2
(en)
*
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
DE60329910D1
(de)
|
2002-03-29 |
2009-12-17 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
DE10224892A1
(de)
*
|
2002-06-04 |
2003-12-18 |
Aventis Pharma Gmbh |
Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
US7531553B2
(en)
*
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
EP1608369B1
(en)
*
|
2003-03-28 |
2013-06-26 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
WO2004110990A2
(en)
|
2003-05-15 |
2004-12-23 |
Arqule, Inc. |
Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
DE10344223A1
(de)
*
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
PT1682126E
(pt)
|
2003-10-16 |
2009-10-02 |
Novartis Vaccines & Diagnostic |
Benzazois substituídos e sua utilização como inibidores da quinase raf
|
DE10349587A1
(de)
*
|
2003-10-24 |
2005-05-25 |
Merck Patent Gmbh |
Benzimidazolylderivate
|
AU2004293018B2
(en)
*
|
2003-11-19 |
2010-02-18 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
GB0401334D0
(en)
*
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
US7470712B2
(en)
|
2004-01-21 |
2008-12-30 |
Bristol-Myers Squibb Company |
Amino-benzazoles as P2Y1 receptor inhibitors
|
TW200536851A
(en)
|
2004-01-23 |
2005-11-16 |
Amgen Inc |
Compounds and methods of use
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
EP1761506A1
(en)
*
|
2004-06-15 |
2007-03-14 |
AstraZeneca AB |
Substituted quinazolones as anti-cancer agents
|
TW200616974A
(en)
*
|
2004-07-01 |
2006-06-01 |
Astrazeneca Ab |
Chemical compounds
|
US7829560B2
(en)
*
|
2004-07-08 |
2010-11-09 |
Arqule, Inc. |
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
|
MX2007002208A
(es)
*
|
2004-08-25 |
2007-05-08 |
Targegen Inc |
Compuestos hetrociclicos y metodos de uso.
|
CN101048388A
(zh)
*
|
2004-08-31 |
2007-10-03 |
阿斯利康(瑞典)有限公司 |
喹唑啉酮衍生物及其作为B-Raf抑制剂的用途
|
MX2007002433A
(es)
*
|
2004-09-01 |
2007-05-04 |
Astrazeneca Ab |
Derivados de quinazolinona y su uso como inhibidores de b-raf.
|
JP2008516939A
(ja)
*
|
2004-10-15 |
2008-05-22 |
アストラゼネカ アクチボラグ |
化学化合物
|
CA2584368A1
(en)
*
|
2004-10-19 |
2006-04-27 |
Arqule, Inc. |
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
|
US20060161115A1
(en)
*
|
2004-11-05 |
2006-07-20 |
Fangrow Thomas F |
Soft-grip medical connector
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
UY29300A1
(es)
*
|
2004-12-22 |
2006-07-31 |
Astrazeneca Ab |
Compuestos quimicos
|
EP1674466A1
(en)
*
|
2004-12-27 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
|
US7576090B2
(en)
*
|
2004-12-27 |
2009-08-18 |
4Sc Ag |
Benzazole analogues and uses thereof
|
US7429608B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Amgen Inc. |
Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
|
EP1924573A1
(en)
*
|
2005-01-25 |
2008-05-28 |
AstraZeneca AB |
B-raf inhibitors
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
TWI370820B
(en)
|
2005-04-27 |
2012-08-21 |
Takeda Pharmaceutical |
Fused heterocyclic compounds
|
WO2006124780A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Kalypsys, Inc. |
Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
|
US20100017895A1
(en)
|
2005-07-18 |
2010-01-21 |
Amy Weiner |
Small animal model for hcv replication
|
CN101253169B
(zh)
*
|
2005-08-30 |
2011-11-23 |
诺瓦提斯公司 |
取代的苯并咪唑及其制备方法
|
TW200804345A
(en)
*
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
EP1943226A2
(en)
|
2005-10-13 |
2008-07-16 |
Smithkline Beecham Corporation |
Phenol ethers as modulators of the opioid receptors
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
EP1951298A1
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
EP2368572B1
(en)
|
2005-11-04 |
2020-03-04 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
NZ567978A
(en)
|
2005-11-04 |
2011-09-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
JP2009520784A
(ja)
*
|
2005-12-22 |
2009-05-28 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体、その製造方法および抗癌剤としてのその使用
|
US20070155746A1
(en)
*
|
2005-12-23 |
2007-07-05 |
Kalypsys, Inc. |
Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
CA2642665C
(en)
|
2006-02-09 |
2013-01-08 |
Daiichi Sankyo Company, Limited |
Anti-cancer pharmaceutical composition
|
EP1987028A2
(en)
*
|
2006-02-10 |
2008-11-05 |
Transtech Pharma, Inc. |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
WO2007108936A2
(en)
|
2006-03-15 |
2007-09-27 |
Wyeth |
N-substituted-azacyclylamines as histamine-3 antagonists
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
CA2649913A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Wyeth |
N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
US7932390B2
(en)
|
2006-06-29 |
2011-04-26 |
Hoffman-La Roche Inc. |
Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
PL2046292T3
(pl)
|
2006-07-21 |
2010-08-31 |
Novartis Ag |
Preparaty eterów benzymidazolilo-pirydylowych
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
PE20080766A1
(es)
|
2006-08-30 |
2008-06-15 |
Novartis Ag |
Sales de benzimidazolil piridil eteres y formulaciones que las contienen
|
MX2009002377A
(es)
|
2006-09-07 |
2009-03-13 |
Biogen Idec Inc |
Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
|
EP3456348A1
(en)
|
2006-09-11 |
2019-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
PE20081152A1
(es)
|
2006-10-06 |
2008-08-10 |
Wyeth Corp |
Azaciclilaminas n-sustituidas como antagonistas de histamina-3
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
MY148438A
(en)
*
|
2007-03-02 |
2013-04-30 |
Novartis Ag |
Solid forms of a raf kinase inhibitor
|
KR20100017866A
(ko)
*
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
US8304557B2
(en)
|
2007-06-05 |
2012-11-06 |
Takeda Pharmaceutical Company Limited |
Fused heterocycle derivatives and use thereof
|
EP2484377A1
(en)
|
2007-06-27 |
2012-08-08 |
Novartis AG |
Low-additive influenza vaccines
|
CL2008002088A1
(es)
|
2007-07-16 |
2008-09-05 |
Wyeth Corp |
Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros.
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
MX2010001636A
(es)
|
2007-08-14 |
2010-03-15 |
Hoffmann La Roche |
Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
|
JP5270553B2
(ja)
*
|
2007-08-23 |
2013-08-21 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
WO2009028629A1
(ja)
*
|
2007-08-29 |
2009-03-05 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
WO2009028655A1
(ja)
*
|
2007-08-30 |
2009-03-05 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
BRPI0816881A2
(pt)
|
2007-09-21 |
2015-03-17 |
Array Biopharma Inc |
Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
|
BRPI0818003A2
(pt)
*
|
2007-10-18 |
2019-09-24 |
Novartis Ag |
inibidores de csf-1r, composições e métodos de uso
|
EP2220078B1
(en)
*
|
2007-10-29 |
2013-05-22 |
Amgen, Inc |
Benzomorpholine derivatives and methods of use
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
PE20091523A1
(es)
|
2007-12-20 |
2009-10-29 |
Novartis Ag |
Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
|
WO2009111279A1
(en)
*
|
2008-02-29 |
2009-09-11 |
Array Biopharma Inc. |
Pyrazole [3, 4-b] pyridine raf inhibitors
|
AU2009222143A1
(en)
*
|
2008-02-29 |
2009-09-11 |
Array Biopharma Inc. |
Raf inhibitor compounds and methods of use thereof
|
EP2265574A1
(en)
*
|
2008-02-29 |
2010-12-29 |
Array Biopharma, Inc. |
N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
|
ES2392482T3
(es)
*
|
2008-02-29 |
2012-12-11 |
Array Biopharma, Inc. |
Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
|
KR20100135766A
(ko)
|
2008-03-18 |
2010-12-27 |
노파르티스 아게 |
인플루엔자 바이러스 백신 항원 제조의 개선
|
AU2009257487B2
(en)
*
|
2008-06-13 |
2013-01-31 |
Novartis Ag |
Substituted benzimidazoles for neurofibromatosis
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
WO2010064611A1
(ja)
|
2008-12-01 |
2010-06-10 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
MX2011005788A
(es)
*
|
2008-12-05 |
2011-06-21 |
Arqule Inc |
Inhibidores raf y sus usos.
|
JP2012516345A
(ja)
*
|
2009-01-29 |
2012-07-19 |
ノバルティス アーゲー |
星細胞腫治療用置換ベンゾイミダゾール
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
KR20120027276A
(ko)
|
2009-04-27 |
2012-03-21 |
노파르티스 아게 |
인플루엔자를 예방하기 위한 면역증강된 백신
|
CN104219954B
(zh)
|
2009-06-23 |
2017-03-22 |
翻译基因组学研究院 |
苯甲酰胺衍生物
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
AU2010269961A1
(en)
|
2009-07-07 |
2012-02-02 |
Novartis Ag |
Conserved Escherichia coli immunogens
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011080595A2
(en)
|
2009-12-30 |
2011-07-07 |
Novartis Ag |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP2593434A1
(en)
|
2010-07-16 |
2013-05-22 |
Purdue Pharma LP |
Pyridine compounds as sodium channel blockers
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
KR20130056345A
(ko)
|
2010-09-17 |
2013-05-29 |
퍼듀 퍼머 엘피 |
피리딘 화합물 및 그의 용도
|
RU2632900C2
(ru)
*
|
2010-11-19 |
2017-10-11 |
Лиганд Фармасьютикалс Инкорпорейтед |
Гетероциклические амины и их применение
|
US8674113B2
(en)
|
2010-12-10 |
2014-03-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US8486968B2
(en)
|
2010-12-10 |
2013-07-16 |
Boehringer Ingelheim International Gmbh |
Compounds
|
EP4159232A1
(en)
|
2011-01-26 |
2023-04-05 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
UY33883A
(es)
|
2011-01-31 |
2012-08-31 |
Novartis Ag |
Novedosos derivados heterocíclicos
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
CN102432595B
(zh)
*
|
2011-09-14 |
2013-09-25 |
湖南有色凯铂生物药业有限公司 |
N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
|
WO2013061305A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Novel purine derivatives and their use in the treatment of disease
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
WO2013136170A1
(en)
|
2012-03-16 |
2013-09-19 |
Purdue Pharma L.P. |
Substituted pyridines as sodium channel blockers
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
ES2826555T3
(es)
|
2012-11-30 |
2021-05-18 |
Glaxosmithkline Biologicals Sa |
Antígenos de Pseudomonas y combinación de antígenos
|
WO2014096941A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Pharma L.P. |
Cyclic sulfonamides as sodium channel blockers
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
WO2015031564A2
(en)
*
|
2013-08-30 |
2015-03-05 |
University Of Utah |
Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors
|
CN103450093A
(zh)
*
|
2013-09-06 |
2013-12-18 |
中国药科大学 |
2-苄氨基苯并咪唑类化合物及其用途
|
WO2015041533A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
JP2016539149A
(ja)
|
2013-12-06 |
2016-12-15 |
ノバルティス アーゲー |
アルファ−アイソフォーム選択的ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
WO2015103317A1
(en)
*
|
2013-12-30 |
2015-07-09 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
US10730866B2
(en)
|
2014-04-07 |
2020-08-04 |
Purdue Pharma L.P. |
Indole derivatives and use thereof
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
EP3623371A1
(en)
|
2014-12-16 |
2020-03-18 |
Axovant Sciences GmbH |
Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
|
CN105949178B
(zh)
*
|
2015-03-09 |
2020-05-26 |
西格莱(苏州)生物医药有限公司 |
一种苯并咪唑类化合物、其制备方法、中间体及应用
|
US10807983B2
(en)
|
2015-03-16 |
2020-10-20 |
Ligand Pharmaceuticals, Inc. |
Imidazo-fused heterocycles and uses thereof
|
RU2017145964A
(ru)
|
2015-06-10 |
2019-07-10 |
Аксовант Сайенсиз Гмбх |
Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
|
EP3334740A4
(en)
|
2015-08-12 |
2019-02-06 |
Axovant Sciences GmbH |
GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
|
KR101770310B1
(ko)
|
2015-08-24 |
2017-08-24 |
이화여자대학교 산학협력단 |
2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
CN109715163B
(zh)
|
2016-09-19 |
2022-11-22 |
诺华股份有限公司 |
包含raf抑制剂和erk抑制剂的治疗组合
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
JP7094942B2
(ja)
*
|
2017-03-15 |
2022-07-04 |
住友ファーマ株式会社 |
ベンズイミダゾール誘導体の製造方法
|
ES2952265T3
(es)
|
2017-05-02 |
2023-10-30 |
Novartis Ag |
Terapia combinada que comprende un inhibidor de Raf y trametinib
|
EP3849536A4
(en)
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
EP3876930A4
(en)
*
|
2018-11-07 |
2022-07-20 |
Dana-Farber Cancer Institute, Inc. |
BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND THEIR USES
|
CN111848505A
(zh)
*
|
2019-04-26 |
2020-10-30 |
广东东阳光药业有限公司 |
一种伐度司他中间体的制备方法
|
EP4039676A4
(en)
*
|
2019-10-02 |
2024-04-03 |
Klotho Sciences |
COMPOUND INTENDED TO INDUCE THE EXPRESSION OF AN ANTI-AGING KLOTHO GENE AND USE THEREOF
|
CN111138428B
(zh)
*
|
2019-12-26 |
2021-02-19 |
深圳市老年医学研究所 |
一种非洲防己碱制备方法以及非洲防己碱
|
WO2021226261A1
(en)
|
2020-05-06 |
2021-11-11 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
US20240051970A1
(en)
*
|
2020-12-16 |
2024-02-15 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
TW202241889A
(zh)
|
2020-12-23 |
2022-11-01 |
美商雅捷可斯治療公司 |
作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑
|
EP4269394A4
(en)
*
|
2021-01-29 |
2024-07-24 |
Korea Res Inst Chemical Tech |
BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM AS ACTIVE INGREDIENT
|
CA3234638A1
(en)
*
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
CN114276266A
(zh)
*
|
2021-12-30 |
2022-04-05 |
兰州康鹏威耳化工有限公司 |
一种4-氨基-2-氟苯甲酰胺的制备方法
|